U.S. Food and Drug Administration staffers said a diabetes drug called canagliflozin, which Johnson & Johnson submitted for review, may carry heart risks.
The development could jeopardize Johnson & Johnson’s ambitions in the profitable diabetes medication market, Bloomberg reports.
The pill, which Johnson & Johnson proposed marketing under the name Invokana, is part of a new class of diabetes treatments aimed at cutting side effects from current drugs. Variations are being developed ...
continue reading...